Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial.

The Lancet. Oncology - 1 Sept 2021

de Bono Johann S, Mehra Niven, Scagliotti Giorgio V, Castro Elena, Dorff Tanya, Stirling Adam, Stenzl Arnulf, Fleming Mark T, Higano Celestia S, Saad Fred, Buttigliero Consuelo, van Oort Inge M, Laird A Douglas, Mata Marielena, Chen Hsiang-Chun, Healy Cynthia G, Czibere Akos, Fizazi Karim

Abstract excerpt

BACKGROUND: Poly(ADP-ribose) polymerase (PARP) inhibitors have antitumour activity against metastatic castration-resistant prostate cancers with DNA damage response (DDR) alterations in genes involved directly or indirectly in homologous recombination repair (HRR). In this study, we assessed the PARP inhibitor talazoparib in metastatic castration-resistant prostate cancers with DDR-HRR alterations. METHODS: In...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to DNA Repair

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug-Related Side Effects and Adverse Reactions

Share to Neoplasm Metastasis

Share to Phthalazines

Share to Poly(ADP-ribose) Polymerase Inhibitors

Share to Prostatic Neoplasms, Castration-Resistant

Share to Survival Analysis

Source

Identifiers

PMID: 34388386
DOI: 10.1016/S1470-2045(21)00376-4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial.PMID 34388386Read ↗

PARP Inhibitors in Metastatic Castration-Resistant Prostate Cancer: Unraveling the Therapeutic LandscapeSemantic proximity Read ↗

PARP inhibitors as a new therapeutic option in metastatic prostate cancer: a systematic review.Semantic proximity Read ↗

First-line combination treatment with PARP and androgen receptor–signaling inhibitors in HRR-deficient mCRPC: Applying clinical study findings to clinical practice in the United StatesSemantic proximity Read ↗

Integrating PARP Inhibitors in mCRPC Therapy: Current Strategies and Emerging TrendsSemantic proximity Read ↗

Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial.Semantic proximity Read ↗

Targeting DNA RepairSemantic proximity Read ↗

Prostate cancer and PARP inhibitors: progress and challengesSemantic proximity Read ↗

Identification of Novel Biomarkers of Homologous Recombination Defect in DNA Repair to Predict Sensitivity of Prostate Cancer Cells to PARP-InhibitorsSemantic proximity Read ↗

Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 StudySemantic proximity Read ↗

Clinical Application of Poly(ADP-ribose) Polymerase (PARP) Inhibitors in Prostate CancerSemantic proximity Read ↗

DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.Semantic proximity Read ↗

Olaparib for Metastatic Castration-Resistant Prostate CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.